Valuation: China Isotope & Radiation Corporation

Market Cap 3.59B 4.2B 536M 472M 447M 403M 760M 51.36B 770M 5.35B 2.06B 26.26B 2.01B 1.97B 84.18B P/E 2024
8.03x
P/E 2025 17.7x
Enterprise Value 3.71B 4.34B 553M 487M 462M 417M 786M 53.06B 796M 5.52B 2.13B 27.12B 2.08B 2.03B 86.96B EV / Sales 2024
0.42x
EV / Sales 2025 0.82x
Free-Float
91.21%
Yield 2024
3.74%
Yield 2025 1.69%
Sep. 22 China Isotope & Radiation Unit's Lu-177 API Filing Clears US FDA Review MT
Aug. 28 China Isotope & Radiation Corporation Reports Earnings Results for the Half Year Ended June 30, 2026 CI
Aug. 28 China Isotope & Radiation Corporation Proposes Interim Dividend for the Six Months Ended 30 June 2026, Payable on 18 December 2026 CI
Aug. 28 China Isotope & Radiation Corporation Announces Resignation of Zhang Junqi as an Executive Director, A Member of the Strategy Committee of the Board and A Member of the Science and Technology Innovation Committee of the Board, Effective August 28, 2026 CI
Aug. 28 China Isotope & Radiation Corporation Announces CEO Changes, Effective August 28, 2026 CI
Jul. 05 China Isotope to Form JV With Associate MT
Jul. 03 China Isotope & Radiation Corporation and CNNC Yuanke Enter into Shareholders? Agreement to Establish Joint Venture Company CNNC Fuyuan CI
Jun. 18 China Isotope & Radiation Corporation Approves Final Dividend for the Year Ended 31 December 2025, Payable on Before 17 August 2026 CI
Jun. 18 China Isotope & Radiation Corporation Appoints Zhang Guoliang as A Member of Legal Affairs Committee of the Board and A Member of Science and Technology Innovation Committee of the Board CI
May. 26 China Isotope Proposes Auditor Change MT
May. 26 China Isotope & Radiation Corporation Announces Ma Xiaoyu Resignation of Ma Xiaoyu as an Executive Director Member of the Legal Affairs Committee Science and Technology Innovation Committee, Effective May 26, 2026 CI
Mar. 27 China Isotope & Radiation final cash dividend of RMB0.2264 per share RE
Mar. 27 China Isotope & Radiation Corporation Proposes Final Dividend for the Year Ended December 31, 2025, Payable Before 17 August 2026 CI
1 day-1.05%
1 week-6.14%
1 month-20.99%
3 months-24.91%
6 months-34.04%
Current year-34.95%
1 week 13.02
Extreme 13.02
14.05
1 month 13.02
Extreme 13.02
17.49
Current year 13.02
Extreme 13.02
24.28
1 year 13.02
Extreme 13.02
25
3 years 9.03
Extreme 9.03
25
5 years 9.03
Extreme 9.03
26.5
10 years 9.03
Extreme 9.03
35.4
Manager TitleAgeSince
Corporate Secretary - 2024-08-29
Corporate Secretary - 2024-08-29
Comptroller/Controller/Auditor 52 2015-12-17
Director TitleAgeSince
Director/Board Member 57 2017-02-21
Director/Board Member 54 2019-06-27
Director/Board Member 54 2019-12-29
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%-6.14%-18.13%+8.06% 536M
-2.10%-4.50%-26.21%+2.04% 171B
-0.92%-3.37%-9.40%+10.12% 110B
-0.90%+0.73%-25.50%+0.78% 106B
+0.69%-2.90%-47.25%-11.84% 75.99B
-2.39%-3.85%-3.93%+66.83% 57.3B
-1.63%-1.93%-4.37%-30.76% 48.76B
+2.40%+4.34%+17.32%+59.27% 50.19B
-2.11%+0.03%-18.27%+19.42% 41.14B
-0.40%-1.64%+28.24%-7.51% 32.56B
Average -0.41%-1.93%-10.75%+11.64% 69.35B
Weighted average by Cap. +0.05%-2.07%-16.17%+9.39%

Financials

2024 2025
Net sales 7.57B 8.86B 1.13B 994M 942M 851M 1.6B 108B 1.62B 11.27B 4.34B 55.35B 4.24B 4.15B 177B 7.19B 8.41B 1.07B 944M 894M 807M 1.52B 103B 1.54B 10.7B 4.12B 52.52B 4.02B 3.94B 168B
Net income 407M 476M 60.62M 53.38M 50.58M 45.66M 86.06M 5.81B 87.18M 605M 233M 2.97B 228M 223M 9.53B 327M 383M 48.81M 42.98M 40.73M 36.77M 69.3M 4.68B 70.19M 487M 188M 2.39B 183M 179M 7.67B
Net Debt -109M -127M -16.24M -14.3M -13.55M -12.23M -23.05M -1.56B -23.35M -162M -62.38M -796M -60.98M -59.65M -2.55B 119M 139M 17.72M 15.6M 14.78M 13.34M 25.15M 1.7B 25.48M 177M 68.06M 868M 66.53M 65.07M 2.78B
Logo China Isotope & Radiation Corporation
China Isotope & Radiation Corp is a China-based company mainly engaged in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products. The Company operates five business segments. Pharmaceuticals segment is engaged in providing imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test (UBT) kits and analyzers and in vitro diagnostic reagents and kits. Radioactive Source Products segment is engaged in providing various medical and industrial radioactive sources products as well as provision of related technical services. Irradiation segment is engaged in providing sterilization services. Radiation Therapy Equipment and Related Services segment is engaged in manufacturing Radiation therapy equipment. Other Businesses segment is engaged in providing trade services in relation to imported radioactive source, medical nuclides, imported radiopharmaceuticals, and other products.
Employees
3,655
Date Price Change Volume
26-09-30 HK$13.14 -1.05% 86,200
26-09-29 HK$13.28 -1.92% 54,600
26-09-28 HK$13.54 -0.44% 64,600
26-09-25 HK$13.60 -3.82% 100,000
26-09-24 HK$14.14 +1.00% 53,800

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1763 Stock